Table 1

Study subject demographics and baseline clinical characteristics

fT>MIC sufficient (n=14)fT>MIC not sufficient (n=13)P value
Age,* predicted mean years (SE)9.7 (1.3)10.2 (1.3)0.788
Gender† (n, % female)8 (57)4 (31)0.168
Race,† n (%)0.076
 White10 (71)12 (92)
 Black4 (29)0 (0)
 Other0 (0)1 (8)
Ethnicity,† n (%)0.345
 Hispanic4 (29)6 (46)
 Not Hispanic10 (71)7 (54)
CFTR genotype,† n (%)0.020
 F508del homozygous3 (21)9 (69)
 F508del heterozygous7 (50)4 (31)
 Other4 (29)0 (0)
Disease stage,† n (%)0.511
 Early (FEV1>70%)12 (86)11 (84)
 Intermediate (FEV1 40%–70%)0 (0)1 (8)
 Advanced (FEV1<40%)0 (0)0 (0)
 NA (age<6 years)2 (14)1 (8)
BMI,* predicted mean (SE)16.7 (1.2)17.6 (1.3)0.859
Maintenance azithromycin,† n (% yes)1 (7)3 (23)0.244
Maintenance inhaled antibiotic,† n (% yes)5 (36)5 (38)0.833
CFTR modulator,† n (% yes)2 (14)5 (38)0.152
Home insulin,† n (% yes)1 (7)0 (0)0.326
Baseline lung function,‡ predicted mean (SE)(n=12)(n=12)
 % predicted FEV186.8 (5.68)106.1 (5.68)0.053
 % predicted FVC93.1 (5.79)106.8 (5.79)0.175
 % predicted FEF25–7572.6 (12.66)118.8 (12.66)0.037
  • *General linear model with Gaussian family and identity link.

  • †χ2.

  • ‡General linear model with Gaussian family and identity link, controlling for demographic characteristics.

  • §Square transform.

  • BMI, Body Mass Index; CFTR, cystic fibrosis transmembrane conductance regulator; FEF25–75, forced expiratory flow 25–75; FEV1, forced expiratory volume in one second; fT>MIC, time above the minimum inhibitory concentration; FVC, forced vital capacity.